ACTU – actuate therapeutics, inc. - common stock (US:NASDAQ)
Stock Stats
News
Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer [Seeking Alpha]
Actuate Therapeutics (NASDAQ: ACTU) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $20.00 price target on the stock.
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer [Yahoo! Finance]
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February
Form 4 ACTUATE THERAPEUTICS, For: Apr 01 Filed by: SCHMITT DANIEL M
Form 4 ACTUATE THERAPEUTICS, For: Apr 01 Filed by: Mazar Andrew Paul
Form 4 ACTUATE THERAPEUTICS, For: Apr 01 Filed by: LYTLE PAUL J
Form S-1 ACTUATE THERAPEUTICS,
Form 8-K ACTUATE THERAPEUTICS, For: Mar 27
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.